TY - JOUR
T1 - Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma
T2 - Final analysis of the GAUSS study
AU - Sehn, Laurie H.
AU - Goy, Andre
AU - Offner, Fritz C.
AU - Martinelli, Giovanni
AU - Caballero, M. Dolores
AU - Gadeberg, Ole
AU - Baetz, Tara
AU - Zelenetz, Andrew D.
AU - Gaidano, Gianluca
AU - Fayad, Luis E.
AU - Buckstein, Rena
AU - Friedberg, Jonathan W.
AU - Crump, Michael
AU - Jaksic, Branimir
AU - Zinzani, Pier Luigi
AU - Iyer, Swaminathan Padmanabhan
AU - Sahin, Deniz
AU - Chai, Akiko
AU - Fingerle-Rowson, Günter
AU - Press, Oliver W.
N1 - Publisher Copyright:
Copyright © 2015 American Society of Clinical Oncology. All rights reserved.
PY - 2015/10/20
Y1 - 2015/10/20
N2 - Purpose: Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma. This is the first prospective, randomized study comparing safety and efficacy of obinutuzumab with rituximab in relapsed indolent lymphoma. The primary end point of this study was the overall response rate (ORR) in patients with follicular lymphoma after induction and safety in patients with indolent lymphoma Patients and Methods: A total of 175 patients with relapsed CD20+ indolent lymphoma requiring therapy and with previous response to a rituximab-containing regimen were randomly assigned (1:1) to four once-per-week infusions of either obinutuzumab (1,000 mg) or rituximab (375 mg/m2). Patients without evidence of disease progression after induction therapy received obinutuzumab or rituximab maintenance therapy every 2 months for up to 2 years. Results: Among patients with follicular lymphoma (n = 149), ORR seemed higher for obinutuzumab than rituximab (44.6% v 33.3%; P = .08). This observation was also demonstrated by a blinded ndependent review panel that measured a higher ORR for obinutuzumab (44.6% v 26.7%; P = 01). However, this difference did not translate into an improvement in progression-free survival No new safety signals were observed for obinutuzumab, and the incidence of adverse events was balanced between arms, with the exception of infusion-related reactions and cough, which were higher in the obinutuzumab arm. Conclusion: Obinutuzumab demonstrated a higher ORR without appreciable differences in safety compared with rituximab. However, the clinical benefit of obinutuzumab in this setting remains unclear and should be evaluated within phase III trials.
AB - Purpose: Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma. This is the first prospective, randomized study comparing safety and efficacy of obinutuzumab with rituximab in relapsed indolent lymphoma. The primary end point of this study was the overall response rate (ORR) in patients with follicular lymphoma after induction and safety in patients with indolent lymphoma Patients and Methods: A total of 175 patients with relapsed CD20+ indolent lymphoma requiring therapy and with previous response to a rituximab-containing regimen were randomly assigned (1:1) to four once-per-week infusions of either obinutuzumab (1,000 mg) or rituximab (375 mg/m2). Patients without evidence of disease progression after induction therapy received obinutuzumab or rituximab maintenance therapy every 2 months for up to 2 years. Results: Among patients with follicular lymphoma (n = 149), ORR seemed higher for obinutuzumab than rituximab (44.6% v 33.3%; P = .08). This observation was also demonstrated by a blinded ndependent review panel that measured a higher ORR for obinutuzumab (44.6% v 26.7%; P = 01). However, this difference did not translate into an improvement in progression-free survival No new safety signals were observed for obinutuzumab, and the incidence of adverse events was balanced between arms, with the exception of infusion-related reactions and cough, which were higher in the obinutuzumab arm. Conclusion: Obinutuzumab demonstrated a higher ORR without appreciable differences in safety compared with rituximab. However, the clinical benefit of obinutuzumab in this setting remains unclear and should be evaluated within phase III trials.
UR - http://www.scopus.com/inward/record.url?scp=84944960445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944960445&partnerID=8YFLogxK
U2 - 10.1200/JCO.2014.59.2139
DO - 10.1200/JCO.2014.59.2139
M3 - Article
C2 - 26282650
AN - SCOPUS:84944960445
SN - 0732-183X
VL - 33
SP - 3467
EP - 3474
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 30
ER -